Vestor Capital LLC Increases Stock Position in McKesson Co. (NYSE:MCK)

Vestor Capital LLC increased its holdings in shares of McKesson Co. (NYSE:MCK - Free Report) by 968.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,257 shares of the company's stock after buying an additional 7,484 shares during the quarter. Vestor Capital LLC's holdings in McKesson were worth $4,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Millstone Evans Group LLC acquired a new stake in McKesson during the 4th quarter worth about $28,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of McKesson during the third quarter worth about $31,000. Synergy Asset Management LLC acquired a new position in McKesson in the 4th quarter worth approximately $32,000. Crews Bank & Trust purchased a new position in McKesson during the 4th quarter worth approximately $33,000. Finally, Atala Financial Inc acquired a new stake in McKesson during the 4th quarter valued at approximately $34,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Trading Down 0.2 %

MCK stock traded down $1.15 during midday trading on Wednesday, reaching $662.45. The stock had a trading volume of 737,849 shares, compared to its average volume of 802,259. McKesson Co. has a 52-week low of $464.42 and a 52-week high of $670.79. The company has a market cap of $83.02 billion, a price-to-earnings ratio of 30.33, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. The company's fifty day simple moving average is $619.05 and its 200 day simple moving average is $576.50.

Remove Ads

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Sell-side analysts predict that McKesson Co. will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be given a $0.71 dividend. The ex-dividend date is Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a yield of 0.43%. McKesson's dividend payout ratio is currently 13.00%.

Insider Transactions at McKesson

In other McKesson news, EVP Leann B. Smith sold 579 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total transaction of $331,645.41. Following the transaction, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian S. Tyler sold 8,961 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $597.99, for a total value of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares in the company, valued at $36,276,465.36. This represents a 12.87 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,689 shares of company stock worth $11,187,351. 0.11% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Bank of America cut their price target on McKesson from $680.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Evercore ISI lifted their price target on McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Mizuho began coverage on McKesson in a report on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price target for the company. Citigroup dropped their price objective on shares of McKesson from $713.00 to $677.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. Finally, Morgan Stanley raised their price target on shares of McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a research report on Tuesday, December 17th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, McKesson has an average rating of "Moderate Buy" and an average target price of $649.36.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.